盟科药业拟定增募资10.33亿元 海鲸药业将入主盟科、赋能产品商业化进程

Core Viewpoint - Mengke Pharmaceutical plans to raise no more than 1.033 billion yuan through a targeted private placement, with the funds allocated entirely for daily research and operational investments [1][2] Group 1: Fundraising and Shareholding Changes - The targeted placement will involve Nanjing Haiqing Pharmaceutical Co., which will acquire a 20% stake in Mengke Pharmaceutical, making it the controlling shareholder and changing the company's previous status of having no controlling shareholder [1][3] - The fundraising aims to supplement operational funds, promote business development, ensure research investment, and enhance the company's core competitiveness [2] Group 2: Strategic Cooperation and Industry Position - Mengke Pharmaceutical and Haiqing Pharmaceutical signed a strategic cooperation agreement to collaborate in product commercialization, production synergy, research innovation, and capital cooperation [4] - Haiqing Pharmaceutical, as an industrial investor, is expected to enhance Mengke Pharmaceutical's commercialization capabilities and improve sales scale and efficiency [5] Group 3: Research and Development Pipeline - Mengke Pharmaceutical has several antibacterial new drugs in clinical development, including MRX-4 and MRX-8, which require substantial funding for their advancement [2][6] - The funds raised will accelerate the development of the company's research pipeline and facilitate the commercialization of research outcomes [6]